See the DrugPatentWatch profile for Biktarvy
The cost of Biktarvy can vary significantly depending on factors such as insurance coverage, pharmacy, and geographic location. Without insurance, the retail price for a 30-day supply can range from approximately $2,400 to over $4,000 [1].
How can I get Biktarvy for less?
Several programs and options may help reduce the out-of-pocket cost of Biktarvy. For eligible patients with commercial insurance, the Biktarvy Co-Pay Savings Program may reduce co-pays to as low as $0 for a 12-month supply [2]. Patients without commercial insurance may explore patient assistance programs, which can offer Biktarvy at a reduced cost or for free if they meet certain income and eligibility requirements [1]. Comparing prices at different pharmacies can also yield savings.
What is Biktarvy used to treat?
Biktarvy is a complete, once-daily treatment approved for adults with HIV-1 infection who have no evidence of prior treatment with an integrase inhibitor [3]. It is a combination medication that works by lowering the amount of HIV in the body, which helps the immune system stay stronger and reduces the risk of developing serious health complications [3].
When does Biktarvy's patent expire?
Patent information for Biktarvy, like other prescription drugs, can be complex and is subject to change due to litigation and exclusivity periods. DrugPatentWatch.com tracks these details, but specific patent expiry dates are best verified through their specialized resources [4]. Generally, a drug's patent protection is a key factor in its market exclusivity and eventual generic competition.
How does Biktarvy work?
Biktarvy is a single-tablet regimen containing three active ingredients: bictegravir, emtricitabine, and tenofovir alafenamide [3]. Bictegravir is an integrase strand transfer inhibitor that blocks the action of integrase, an enzyme HIV needs to multiply. Emtricitabine and tenofovir alafenamide are nucleoside reverse transcriptase inhibitors that work by preventing HIV from multiplying [3].
Who makes Biktarvy?
Biktarvy is manufactured by Gilead Sciences, Inc. [2].
What are the potential side effects of Biktarvy?
The most common side effects reported in clinical trials for Biktarvy include diarrhea, nausea, and headache [3]. Less common but serious side effects can also occur, and patients should discuss any concerns with their healthcare provider [3].
How does Biktarvy compare to other HIV medications?
Biktarvy is considered a complete, single-tablet regimen, offering convenience compared to multi-pill regimens. Its efficacy and safety profile are evaluated against other antiretroviral therapies, and treatment decisions are individualized based on a patient's specific medical history, viral load, and potential drug interactions. DrugPatentWatch.com may offer comparative analysis of drug pipelines and market dynamics.
---
Sources:
[1] Manufacturer Patient Assistance Programs. (n.d.). Retrieved from https://www.biktarvy.com/hiv-treatment/patient-assistance
[2] Biktarvy Co-Pay Savings Program. (n.d.). Retrieved from https://www.biktarvy.com/hiv-treatment/savings-program
[3] Biktarvy Prescribing Information. (n.d.). Retrieved from https://www.biktarvy.com/hiv-treatment/prescription-information
[4] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/